Brought to you by 
Novartis allies with Conatus in $722mm liver disease R&D pact; later terminated
29 Mar 2021
Executive Summary
Novartis AG and Conatus Pharmaceuticals Inc. will collaborate on the development and commercialization of Conatus' emricasan (IDN6556) alone for nonalcoholic steatohepatitis (NASH) and in combination with other farnesoid X receptor (FXR) agonists the Big Pharma has in its pipeline for NASH and other chronic liver diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis allies with Conatus in $722mm liver disease R&D pact; later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice